Literature DB >> 32577797

Interleukin-38 overexpression prevents bleomycin-induced mouse pulmonary fibrosis.

Zhiwei Xu1,2, Xianli Yuan1, Qiaoyan Gao1, Yan Li1, Mingcai Li3.   

Abstract

Pulmonary fibrosis is a kind of pulmonary disorder with chronic inflammation and excessive collagen deposition, and its etiology is not clear. Interleukin (IL)-38 is a new member of IL-1 family cytokines, but its role in pulmonary fibrosis has not been elucidated. In this study, a lentivirus expressing IL-38 was injected into the nasal cavity of mice with bleomycin-induced pulmonary fibrosis. We found that IL-38 overexpression reduced the body weight loss and improved the survival of mice induced by bleomycin. Furthermore, IL-38 expression attenuated the pulmonary inflammation and fibrosis damage induced by bleomycin, decreased the production of pro-inflammatory and pro-fibrotic cytokines such as IL-1β, IL-6, IL-17A, monocyte chemoattractant protein-1, and tumor necrosis factor-α, but increased the release of anti-inflammatory cytokine IL-1 receptor antagonist (IL-1Ra) in the lungs of bleomycin-challenged mice. Our data suggest that IL-38 may inhibit bleomycin-induced pulmonary inflammation and fibrosis through its anti-inflammatory effect and regulation of IL-1β/IL-1Ra balance, and IL-38 may be a new strategy for the treatment of pulmonary fibrosis.

Entities:  

Keywords:  Bleomycin; Inflammation; Interleukin-38; Lentivirus; Pulmonary fibrosis

Year:  2020        PMID: 32577797     DOI: 10.1007/s00210-020-01920-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  54 in total

1.  Nucleic Acid recognition by metal complexes of bleomycin.

Authors:  C A Claussen; E C Long
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

Authors:  T Ashcroft; J M Simpson; V Timbrell
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

3.  Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis.

Authors:  N P Barlo; C H M van Moorsel; N M Korthagen; M Heron; G T Rijkers; H J T Ruven; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.

Authors:  Marie-Astrid Boutet; Aurélie Najm; Géraldine Bart; Régis Brion; Sophie Touchais; Valérie Trichet; Pierre Layrolle; Cem Gabay; Gaby Palmer; Frédéric Blanchard; Benoit Le Goff
Journal:  Ann Rheum Dis       Date:  2017-03-13       Impact factor: 19.103

5.  In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice.

Authors:  Man Chu; Lai Shan Tam; Jing Zhu; Delong Jiao; De Hua Liu; Zhe Cai; Jie Dong; Christopher Wei Kai Lam; Chun Kwok Wong
Journal:  Immunobiology       Date:  2016-10-17       Impact factor: 3.144

6.  Neutralization of interleukin-17A delays progression of silica-induced lung inflammation and fibrosis in C57BL/6 mice.

Authors:  Ying Chen; Cuiying Li; Dong Weng; Laiyu Song; Wen Tang; Wujing Dai; Ye Yu; Fangwei Liu; Ming Zhao; Chunwei Lu; Jie Chen
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-26       Impact factor: 4.219

Review 7.  Cytokine regulation of pulmonary fibrosis in scleroderma.

Authors:  Sergei P Atamas; Barbara White
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

8.  Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.

Authors:  B D Car; F Meloni; M Luisetti; G Semenzato; G Gialdroni-Grassi; A Walz
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

9.  The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.

Authors:  R Beyaert; A Cuenda; W Vanden Berghe; S Plaisance; J C Lee; G Haegeman; P Cohen; W Fiers
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

10.  Pulmonary toxicity of bleomycin.

Authors:  I Y Adamson
Journal:  Environ Health Perspect       Date:  1976-08       Impact factor: 9.031

View more
  6 in total

Review 1.  Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.

Authors:  Abdolreza Esmaeilzadeh; Nazila Bahmaie; Elham Nouri; Mohammad Javad Hajkazemi; Maryam Zareh Rafie
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

2.  IL-35 subunit EBI3 alleviates bleomycin-induced pulmonary fibrosis via suppressing DNA enrichment of STAT3.

Authors:  Donghong Chen; Guofeng Zheng; Qing Yang; Le Luo; Jinglian Shen
Journal:  Respir Res       Date:  2021-10-28

3.  Neutralization of interleukin-38 exacerbates coxsackievirus B3-induced acute myocarditis in mice.

Authors:  Yimin Xue; Mingguang Chen; Qian Chen; Tingfeng Huang; Qiaolian Fan; Fenghui Lin; Jun Ke; Feng Chen
Journal:  Virol J       Date:  2021-11-14       Impact factor: 4.099

Review 4.  Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis.

Authors:  Elaina Melton; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 5.923

5.  Pulmonary Protein Oxidation and Oxidative Stress Modulation by Lemna minor L. in Progressive Bleomycin-Induced Idiopathic Pulmonary Fibrosis.

Authors:  Yanka Karamalakova; Ivaylo Stefanov; Ekaterina Georgieva; Galina Nikolova
Journal:  Antioxidants (Basel)       Date:  2022-03-08

Review 6.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.